ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Covidien will obtain molybdenum-99 from Poland’s Maria Research Reactor for the manufacture of technetium-99m, an isotope used in more than 80% of all nuclear medicine procedures. FDA and Health Canada have approved the Maria reactor, according to Covidien, a major medical imaging company. Technetium-99m has been in short supply for the past year because of an outage at Canada’s Chalk River reactor, which supplies about half the world’s molybdenum-99. Atomic Energy of Canada said last week that the restart has been delayed by about a month until May.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter